Capecitabine for treatment of advanced hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2310-2314

  Von Delius, Stefan ^a   Lersch, C ^a   Mayr, M ^a   Stock, K ^a   Schulte Frohlinde, E ^a   Schmid, R M ^a   Eckel, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Capecitabine; Chemotherapy; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

CAPECITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 37749035671     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80(6):827-841.
2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350(9085):1142-1143.
3. Deuffic S, Poynard T, Buffat L, Valleron AJ: Trends in primary liver cancer. Lancet 1998; 351(9097):214-215.
4. The Cancer of the Liver Italian Program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: Hepatology 1998; 28(3):751-755.
5. Kew MC: Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology 1989; 97(1):136-139.
6. Kew MC, Popper H: Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984; 4(2):136-146.
7. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362(9399):1907-1917.
8. Simonetti RG, Liberati A, Angiolini C, Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8(2):117-136.
9. Thomas MB, Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23(13):2892-2899.
10. Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005; 27(1):23-44.
11. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5(7):1696-1702.
12. Talwalkar JA, Gores GJ: Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S126-132.
13. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2):429-442.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J: Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734-1739.
15. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):1164-1171.
16. Eklund JW, Trifilio S, Mulcahy MF: Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19(8):1057-1063.
17. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004 1; 101(3):578-586.
18. Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127(5 Suppl 1):S218-224.
19. Farinati F, Rinaldi M, Gianni S, Naccarato R: How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89(11):2266-2273.
20. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clinical trials 1989; 10:1-10.